Metraipolis › archive › dc_f7438aaae49e

Omalizumab-Associated Post-Injection Urticaria Exacerbation and Urticaria-Related Adverse Reactions During Treatment for Chronic Urticaria: A Scoping Review — Europe PMC PMID:42514194

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42514194
DOI
10.3390/life16071124
License (as archived)
solo-consultazione
Archived
2026-10-18T11:04:52.006Z
SHA-256 of the archived text
ac4d4bd34de513d32d455255c198612857a9d9f47a64e0707feb33986ab34c92
Stable URL of this page
https://metraipolis.com/documento/dc_f7438aaae49e

How to cite

Omalizumab-Associated Post-Injection Urticaria Exacerbation and Urticaria-Related Adverse Reactions During Treatment for Chronic Urticaria: A Scoping Review — Europe PMC PMID:42514194 — Europe PMC (en), https://europepmc.org/article/MED/42514194 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f7438aaae49e (Metraipolis archive dc_f7438aaae49e, sha256 ac4d4bd34de513d32d455255c198612857a9d9f47a64e0707feb33986ab34c92)
BibTeX
@misc{dcf7438aaae49e,
  title = {Omalizumab-Associated Post-Injection Urticaria Exacerbation and Urticaria-Related Adverse Reactions During Treatment for Chronic Urticaria: A Scoping Review — Europe PMC PMID:42514194},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42514194},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f7438aaae49e; sha256 ac4d4bd34de513d32d455255c198612857a9d9f47a64e0707feb33986ab34c92},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42514194. Agents can read the archived copy with the MCP tool read_document.